Metabolomics as a Promising Resource Identifying Potential Biomarkers for Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a relapsing chronic disorder of the gastrointestinal tract characterized by disruption of epithelial barrier function and excessive immune response to gut microbiota. The lack of biomarkers providing early diagnosis or defining the status of the pathology difficul...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical medicine Vol. 10; no. 4; p. 622
Main Authors Bauset, Cristina, Gisbert-Ferrándiz, Laura, Cosín-Roger, Jesús
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 06.02.2021
MDPI
Subjects
Antibodies
Biomarkers
Clinical medicine
Health care
Inflammation
Inflammatory bowel disease
Inflammatory diseases
Metabolism
Metabolites
NMR
Nuclear magnetic resonance
Pathology
Patients
Remission (Medicine)
Review
Spectrum analysis
Urine
metabolomics
biomarkers
inflammatory bowel disease
Online AccessGet full text

Cover

More Information
Summary:Inflammatory bowel disease (IBD) is a relapsing chronic disorder of the gastrointestinal tract characterized by disruption of epithelial barrier function and excessive immune response to gut microbiota. The lack of biomarkers providing early diagnosis or defining the status of the pathology difficulties an accurate assessment of the disease. Given the different metabolomic profiles observed in IBD patients, metabolomics may reveal prime candidates to be studied, which may help in understanding the pathology and identifying novel therapeutic targets. In this review, we summarize the most current advances describing the promising metabolites such as lipids or amino acids found through untargeted metabolomics from serum, faecal, urine and biopsy samples.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm10040622